Clinical efficacy of JAK-STAT inhibition and chidamide in chidamide-resistant NKTL
NKTL, death
EPSTEIN, VIRUS, DISEASE
We next assessed whether JAK-STAT inhibition could be a potential therapeutic strategy to overcome resistance to chidamide in the clinic. A 48-year-old Chinese male patient who was initially diagnosed with stage IIA extranodal NKTL of the nasal type was recruited. He was refractory to first-line asparaginase-based chemotherapy. Salvage therapy with a combination of chidamide (30 mg orally, twice a week, continuous) and the anti-programmed death protein 1 (PD-1) antibody sintilimab (200 mg intravenously, on Day 1) was given, but the disease progressed with multiple new lesions accompanied by a dramatic increase in the peripheral blood Epstein–Barr virus (EBV) viral load after four 21-day cycles (Fig. The benefit of combinatorial therapy in relapsed/refractory NKTL patient. 